New York, Nevada, Las Vegas, DelveInsight’s “Acute Myeloid Leukemia Market Insight, Epidemiology and Market Forecast 2032” report provides current treatment practices, emerging drugs, Acute Myeloid Leukemia market share of the individual therapies, current and forecasted Acute Myeloid Leukemia market size from 2019 to 2032 segmented by seven major markets. The report also offers current Acute Myeloid Leukemia therapy algorithms, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Acute Myeloid Leukemia market.

 

Acute Myeloid Leukemia Overview

Acute myeloid leukemia (AML) (also known as acute myelocytic leukemia, acute myelogenous leukemia, acute granulocytic leukemia, and acute non-lymphocytic leukaemia) is a heterogeneous hematologic malignancy characterized by the clonal expansion of myeloid blasts in the peripheral blood, bone marrow, and/or other tissues.

AML can involve tissues outside the bone marrow and blood, including lymph nodes, the brain, skin, and other parts of the body.

AML is the most common acute leukemia in adults and primarily affects older people with a median age of diagnosis ~67 years. Each patient generally has a unique profile of cytogenetic abnormalities. Older age is associated with a higher frequency of abnormalities.

 

Acute Myeloid Leukemia Epidemiological Insights

According to data from the Global Burden of Disease Study 2017, among the EU5 countries, the UK has the highest prevalence of AML, at more than 5,000 cases, while Spain has the lowest at under 2,300 cases.

 

Acute Myeloid Leukemia Treatment Market 

Treatment of most patients with AML typically consists of two chemotherapy phases: remission induction (often just called induction) and consolidation (postremission therapy). There has been a plethora of drugs approved for this aggressive cancer, since 2017. The US FDA has approved glasdegib, venetoclax, ivosidenib, midostaurin, CPX- 351, and gemtuzumab ozogamicin (GO) to treat persons with newly diagnosed acute myeloid leukemia. Likewise, the European Medicines Agency (EMA) has approved midostaurin, CPX-351, and GO.   

 

Promising Therapies in the Acute Myeloid Leukemia Pipeline

• ASTX727
• Dociparstat Sodium
• IO-202
• And others

 

Discover more about Acute Myeloid Leukemia therapies in the pipeline @ Acute Myeloid Leukemia Drugs

 

Leading Companies Working in the Acute Myeloid Leukemia Market

• Astex Pharmaceuticals
• Chimerix
• Immune Onc
• And others

 

To understand key companies related to the Acute Myeloid Leukemia Market, get a snapshot of the Acute Myeloid Leukemia Regulatory and Patent Analysis.

 

Scope of the Acute Myeloid Leukemia Market Report

Study Period: 2019–2032

Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan]

Key Acute Myeloid Leukemia Companies: Astex Pharmaceuticals, Chimerix, Immune Onc, and others

Key Acute Myeloid Leukemia Pipeline Therapies: ASTX727, Dociparstat Sodium, IO-202, and others

Therapeutic Assessment: Acute Myeloid Leukemia current marketed and emerging therapies

Acute Myeloid Leukemia Market Dynamics: Acute Myeloid Leukemia market drivers and barriers 

Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

Unmet Needs, KOL’s views, Analyst’s views, Acute Myeloid Leukemia Market Access and Reimbursement

 

Table of Contents

1. Acute Myeloid Leukemia Market Key Insights

2. Acute Myeloid Leukemia Market Report Introduction

3. Acute Myeloid Leukemia Market Overview at a Glance

4. Acute Myeloid Leukemia Market Executive Summary

5. Disease Background and Overview

6. Acute Myeloid Leukemia Treatment and Management

7. Acute Myeloid Leukemia Epidemiology and Patient Population

8. Patient Journey

9. Acute Myeloid Leukemia Emerging Drugs

10. 7MM Acute Myeloid Leukemia Market Analysis

11. Acute Myeloid Leukemia Market Outlook

12. Potential of Current and Emerging Therapies

13. KOL Views

14. Acute Myeloid Leukemia Market Drivers

15. Acute Myeloid Leukemia Market Barriers

16. Unmet Needs

17. SWOT Analysis

18. Appendix

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

Trending Report Offerings by DelveInsight:

• Gender Dysphoria Market
• Germany Healthcare Outlook Market
• Hyperlipidemia Market
• Mammography Devices Market
• Dental Equipment Market
• Adalimumab Biosimilar Market
• Medical Marijuana Market
• Hyperlipidemia Market
• Metastatic Cutaneous Squamous Cell Cancer Market
• Mucopolysaccharidosis Market

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

 

Contact Us

Kritika Rehani

info@delveinsight.com 

+1(919)321-6187 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/